Bruce Johnson, MD
Medical Oncology · Boston, MANPI 1578523866
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $92,184 of the $120,365 with a category attached, or 76.6%. It is spread thinly across 15 manufacturers, the largest accounting for just 21.8%. Reporting peaked in 2020 at $28,821 and has fallen 70.1% since, to $8,613 in 2025.
Across 85 payments — averaging $1416.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$26K
- Novartis$15K
- Novartis Pharma AG$15K
- Astrazeneca UK Limited$11K
- Merck$9K
- Eli Lilly$9K
- plus $36K from 9 others
Across 46 payments — averaging $45,849 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$2M
- Pfizer$86K
- F. Hoffmann-la Roche AG$11K
What the payments were for
- Consulting fees$92,18477%
- Speaking & faculty fees$5,2734%
- Travel & lodging$21,38318%
- Food & beverage$1,5251%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 21 | $26,250 |
| Novartis | 7 | $14,907 |
| Novartis Pharma AG | 7 | $14,551 |
| Astrazeneca UK Limited | 14 | $11,409 |
| Merck | 3 | $8,613 |
| Eli Lilly | 2 | $8,567 |
| Jazz Pharmaceuticals Inc. | 3 | $7,495 |
| Chugai Pharmaceutical Co., Ltd. | 6 | $6,997 |
| Foundation Medicine, Inc. | 5 | $5,280 |
| Genentech, Inc. | 4 | $4,662 |
| Janssen Scientific Affairs, LLC | 4 | $4,040 |
| F. Hoffmann-la Roche AG | 4 | $3,323 |
| Janssen Global Services, LLC | 2 | $2,185 |
| G1 Therapeutics, Inc. | 1 | $1,950 |
| GSK | 2 | $138 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CANAKINUMAB_ILARIS_IMMUNOLOGY$14,344
- Enhertu$13,871
- TECENTRIQ$8,989
- ILARIS$5,900
- FOUNDATIONACT$5,280
- FOUNDATIONFOCUS$5,280
- FOUNDATIONONE CDX$5,280
- FOUNDATIONONE HEME$5,280
- FOUNDATIONONE$5,280
- PIQRAY$4,125
- Non-Covered Product$4,112
- JZP-815$3,200
- Alecensa$2,805
- COTELLIC$2,805
- GAVRETO$2,805
- ROZLYTREK$2,805
- RYBREVANT$2,185
- COSELA$1,950
- MEKINIST$141
- TAFINLAR$141
How this compares
$120,365 in reported general payments places this provider in the 85th percentile of 308 medical oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XalkoriCrizotinib | 12 | $255,893 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Boston
- George DemetriBoston$1.6M
- Keith FlahertyBoston$932K
- Alicia MorgansBoston$690K
- Pasi Antero JanneBoston$458K
- Robert HaddadBoston$451K
- Irene GhobrialBoston$431K
- Joaquin Bellmunt MolinsBoston$415K
- Jeremy AbramsonBoston$334K
- Justin GainorBoston$324K
- Narjust FlorezBoston$324K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.